STOCK TITAN
  1. Home
  2. News
  3. RYTM

Rhythm Pharmaceuticals Inc. - RYTM STOCK NEWS

Welcome to our dedicated news page for Rhythm Pharmaceuticals (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rhythm Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rhythm Pharmaceuticals's position in the market.

News
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) will report its first quarter 2024 financial results on Tuesday, May 7, 2024. The company will host a live conference call and webcast to provide a corporate update. Additionally, David Meeker, M.D., Chair, President, and CEO, will participate in a fireside chat at the Bank of America 24th Annual Employee Healthcare Conference on Tuesday, May 14, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. announces new employment inducement grants for eight new employees, covering 31,220 shares of common stock through stock options and restricted stock units. The grants are subject to the terms of the Inducement Plan adopted by the board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
none
-
News
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. secures $150 million through a preferred stock sale to fund clinical development and commercialization activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
none
News
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. initiates Phase 1 clinical trial for RM-718, a potential treatment for rare neuroendocrine diseases. The drug aims to reduce hyperphagia and obesity without causing hyperpigmentation. The trial will evaluate safety, tolerability, and pharmacokinetics in three parts, targeting both healthy individuals with obesity and patients with hypothalamic obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
clinical trial
-
News
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. granted inducement equity grants to new employees, covering 13,780 shares of common stock. The grants include stock options and restricted stock units subject to the 2022 Employment Inducement Plan. The options have an exercise price of $41.10 per share and vest over time, while the RSUs vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
-
News
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. (RYTM) will participate in two investor conferences to discuss their progress in rare neuroendocrine diseases. David Meeker, M.D., and Hunter Smith will engage in fireside chats at the Barclays and Needham conferences, respectively, with webcasts available on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
conferences
News
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
Rhea-AI Summary
Rhythm Pharmaceuticals plans to add a cohort of Japanese patients to its global Phase 3 trial for hypothalamic obesity treatment, targeting a significant unmet need in Japan with 5,000 to 8,000 patients estimated. Dosing for the Japanese cohort is expected to start in the third quarter of 2024, with the company aiming for potential approval in Japan. The company also completed enrollment in the pivotal 120-patient cohort for its global Phase 3 trial, with top-line study results expected in the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.73%
Tags
clinical trial
-
News
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
Rhea-AI Summary
Rhythm Pharmaceuticals reported fourth quarter 2023 net revenue of $24.2 million from IMCIVREE sales, completed enrollment in a Phase 3 trial for hypothalamic obesity, acquired global rights to LB54640, and received reimbursement approvals for IMCIVREE in Spain and Italy. The Company also announced Phase 3 development plans for setmelanotide in Japan and the FDA acceptance of an IND application for RM-718. Financially, Rhythm had $275.8 million in cash as of December 31, 2023, with net product revenues of $77.4 million for the full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.73%
Tags
earnings
-
News
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. (RYTM) granted inducement equity grants covering 20,295 shares of its common stock to six new employees. The grants include stock options and restricted stock units (RSUs) subject to the terms of the 2022 Employment Inducement Plan. The options have an exercise price of $44.88 per share and will vest over four years. The RSUs also vest over four years, subject to continued employment. The Inducement Plan was adopted by the board of directors on February 9, 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.63%
Tags
none
News
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. (RYTM) announced that the Italian Medicine Agency approved reimbursement for IMCIVREE for the treatment of obesity and control of hunger associated with Bardet-Biedl syndrome (BBS). This allows families in Italy affected by this rare neuroendocrine disease to access the first and only treatment option authorized in the European Union. BBS is a rare melanocortin-4 receptor (MC4R) pathway disease with hallmark symptoms of hyperphagia and early-onset, severe obesity. AIFA previously approved reimbursement for IMCIVREE for the treatment of obesity and control of hunger associated with other conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
none
Stock RYTM logo
Rhythm Pharmaceuticals Inc.

Nasdaq:RYTM

RYTM Rankings

#1739 Ranked by Market Cap
#2878 Ranked by Stock Gains
N/A Ranked by Dividends

RYTM Stock Data

2.43B
44.99M
0.52%
112.26%
16.19%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About RYTM

rhythm pharmaceuticals inc. is a biotechnology company located in 855 boylston street, 11th floor, boston, ma, united states.